{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:02:19Z","timestamp":1793707339618,"version":"4.6.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5RO1HL132985"],"award-info":[{"award-number":["5RO1HL132985"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jacc.2021.07.056","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:13:35Z","timestamp":1632766415000},"page":"1437-1449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Hepatic Sensing Loop Regulates PCSK9\u00a0Secretion in Response to Inhibitory Antibodies"],"prefix":"10.1016","volume":"78","author":[{"given":"Carlota","family":"Oleaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Friz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagai","family":"Tavori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"W\u00f3jcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Warden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Q.","family":"Purnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Pamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.07.056_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations\u00a0in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2021.07.056_bib2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2021.07.056_bib3","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/bi7016359","article-title":"Self-association of human PCSK9 correlates with its LDLR-degrading activity","volume":"47","author":"Fan","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.jacc.2021.07.056_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2021.07.056_bib5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation","volume":"127","author":"Tavori","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.056_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","article-title":"On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects","volume":"238","author":"Tavori","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2021.07.056_bib7","article-title":"The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol","volume":"2017","author":"Seidah","year":"2017","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.jacc.2021.07.056_bib8","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.056_bib9","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jacl.2019.10.004","article-title":"Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150\u00a0mg doses","volume":"13","author":"Robinson","year":"2019","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2021.07.056_bib10","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.056_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/00325481.2015.998987","article-title":"Safety and efficacy of alirocumab 150\u00a0mg every 2\u00a0weeks, a fully human proprotein convertase subtilisin\/kexin type 9 monoclonal antibody: A Phase II pooled analysis","volume":"127","author":"Koren","year":"2015","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jacc.2021.07.056_bib12","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.07.056_bib13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2485","article-title":"Diagnosing resistance to a proprotein convertase subtilisin\/kexin type 9 inhibitor","volume":"168","author":"Shapiro","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2021.07.056_bib14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7150\/ijbs.3524","article-title":"An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes","volume":"8","author":"Zhang","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jacc.2021.07.056_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/CIRCRESAHA.117.311532","article-title":"Application of PCSK9 inhibitors in practice: challenges and opportunities","volume":"121","author":"Kaufman","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2021.07.056_bib16","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.056_bib17","article-title":"Insights on the kinetics and dynamics of the furin-cleaved form of PCSK9","author":"Oleaga","year":"2020","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.07.056_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.116.025080","article-title":"Factorial Effects of evolocumab and atorvastatin on lipoprotein metabolism","volume":"135","author":"Watts","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.07.056_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","article-title":"The PCSK9 revolution: current status, controversies, and future directions","volume":"30","author":"Warden","year":"2020","journal-title":"Trends Cardiovasc Med"},{"issue":"477","key":"10.1016\/j.jacc.2021.07.056_bib20","doi-asserted-by":"crossref","first-page":"eaat3356","DOI":"10.1126\/scitranslmed.aat3356","article-title":"Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay","volume":"11","author":"Berkhout","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jacc.2021.07.056_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/03009742.2017.1290822","article-title":"Tumour necrosis factor-alpha\/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis","volume":"47","author":"Berthold","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jacc.2021.07.056_bib22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacc.2021.07.056_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2036.2001.00956.x","article-title":"Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease","volume":"15","author":"Cornillie","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jacc.2021.07.056_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/apa.13319","article-title":"Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis","volume":"105","author":"Kahn","year":"2016","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jacc.2021.07.056_bib25","doi-asserted-by":"crossref","first-page":"675108","DOI":"10.1155\/2014\/675108","article-title":"Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-alpha and its soluble receptors during the course of therapy with etanercept and infliximab","volume":"2014","author":"Schulz","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jacc.2021.07.056_bib26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacc.2021.07.056_bib27","first-page":"28","article-title":"Alirocumab (Praluent): first in the new class of PCSK9 inhibitors","volume":"41","author":"Manniello","year":"2016","journal-title":"P\u00a0T"},{"key":"10.1016\/j.jacc.2021.07.056_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.trsl.2012.01.010","article-title":"Serum levels of proprotein convertase subtilisin\/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin\/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways","volume":"160","author":"Cameron","year":"2012","journal-title":"Transl Res"},{"key":"10.1016\/j.jacc.2021.07.056_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1194\/jlr.M087189","article-title":"Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake","volume":"60","author":"Galvan","year":"2019","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.07.056_bib30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41467-017-00568-7","article-title":"Heparan sulfate proteoglycans present PCSK9 to the LDL receptor","volume":"8","author":"Gustafsen","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2021.07.056_bib31","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2021.07.056_bib32","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1074\/jbc.M116.769430","article-title":"The proprotein convertase subtilisin\/kexin type 9-resistant R410S low density lipoprotein receptor mutation: a novel mechanism causing familial hypercholesterolemia","volume":"292","author":"Susan-Resiga","year":"2017","journal-title":"J\u00a0Biol Chem"},{"issue":"Suppl","key":"10.1016\/j.jacc.2021.07.056_bib33","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.07.056_bib34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2","volume":"49","author":"Jeong","year":"2008","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.07.056_bib35","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.07.056_bib36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","article-title":"The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor","volume":"89","author":"Brown","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2021.07.056_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.tibs.2018.01.005","article-title":"SREBPs in lipid metabolism, insulin signaling, and beyond","volume":"43","author":"DeBose-Boyd","year":"2018","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.jacc.2021.07.056_bib38","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.3748\/wjg.v10.i21.3081","article-title":"Maintaining cholesterol homeostasis: sterol regulatory element-binding proteins","volume":"10","author":"Weber","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jacc.2021.07.056_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cmet.2013.12.006","article-title":"The hypercholesterolemia-risk gene SORT1 facilitates\u00a0PCSK9 secretion","volume":"19","author":"Gustafsen","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacc.2021.07.056_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/CIRCRESAHA.118.313648","article-title":"Hepatic glucagon signaling regulates PCSK9 and low-density lipoprotein cholesterol","volume":"124","author":"Spolitu","year":"2019","journal-title":"Circ Res"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2021.07.056_bib41","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2337\/diabetes.51.2007.S3","article-title":"Molecular determinants of regulated exocytosis","volume":"51","author":"Gerber","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2021.07.056_bib42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jcph.840","article-title":"Impact of target-mediated elimination on the dose and regimen of evolocumab, a human monoclonal antibody against proprotein convertase subtilisin\/kexin type 9 (PCSK9)","volume":"57","author":"Gibbs","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jacc.2021.07.056_bib43","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1373\/clinchem.2014.222455","article-title":"Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins","volume":"60","author":"Lassman","year":"2014","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2021.07.056_bib44","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1172\/JCI80025","article-title":"Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects","volume":"125","author":"Millar","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2021.07.056_bib45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bcp.13767","article-title":"Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations","volume":"85","author":"Wang","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2021.07.056_bib46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/BJ20082407","article-title":"Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor","volume":"419","author":"Duff","year":"2009","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.jacc.2021.07.056_bib47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41598-020-79948-x","article-title":"Role of PAI-1 in hepatic steatosis and dyslipidemia","volume":"11","author":"Levine","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2021.07.056_bib48","first-page":"227","article-title":"Factors affecting the antigen-antibody reaction","volume":"5","author":"Reverberi","year":"2007","journal-title":"Blood Transfus"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721058459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721058459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:45:21Z","timestamp":1760017521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721058459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":48,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0735109721058459"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.07.056","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic Sensing Loop Regulates PCSK9\u00a0Secretion in Response to Inhibitory Antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.07.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}